Psychedelic Use Is Linked to Higher Rates of Cannabis Use Disorder ↗
National survey data showing psilocybin and LSD use associated with approximately double the risk of cannabis use disorder, complicating therapeutic psychedelic narratives.
Browse more cannabis research, findings, methods, and limitations.
National survey data showing psilocybin and LSD use associated with approximately double the risk of cannabis use disorder, complicating therapeutic psychedelic narratives.
Analysis of 150,992 college students showing organized sports participation moderates the link between cannabis use and depression, anxiety, and PTSD diagnoses.
Review detailing how the endocannabinoid system regulates both neuronal excitability and neuroinflammation in epilepsy, highlighting dual therapeutic mechanisms.
Scoping review of 152 studies on cannabis use in Indigenous communities finding disproportionately higher use rates and a critical lack of culturally appropriate intervention research.
Preclinical study finding chronic oral THC enhances working memory in aged rats without affecting young adults, suggesting cannabis may help age-related cognitive decline.
Clinical review of cannabis therapeutics establishing strong evidence for 6 conditions while noting mixed evidence for pain, sleep, and psychiatric uses, alongside significant risks.
Preclinical study showing low-dose THC combined with celecoxib reduces Alzheimer's pathology and improves cognition in mice, with both drugs already FDA-approved.
Lab study showing CBD and green tea EGCG complement each other to block SARS-CoV-2 at multiple stages — CBD reduces virus entry receptor while EGCG suppresses spike protein.
Comprehensive review of cannabinoid effects on the immune system, from molecular mechanisms to disease applications, highlighting both therapeutic potential and safety concerns.
Preclinical study showing CBD inhibits colorectal cancer by targeting the HIF-1alpha/LDHA glycolysis pathway, disrupting the metabolic reprogramming that fuels tumor growth.
First study characterizing delta-8-THC's drug interaction potential, finding significant inhibition of CYP2C9 and CYP3A4 liver enzymes with clinically relevant predictions.
Analysis of 2.5 million IBD hospitalizations showing substance use disorders rising from 24% to 28% in Crohn's disease, with cannabis and opioid use disorders growing fastest.
First study of home-grown cannabis after Australian decriminalization: moderate THC (9%), low contamination, but 52% of growers anxious about legal grey areas.
NHANES analysis showing cannabis doubles depression odds, with 11-17% of the effect mediated by combustion-related pollutants (PAHs), suggesting smoking method matters.
Global Burden of Disease analysis showing drug use disorder incidence fell 8% but deaths rose 31% from 1990-2021, with 13.6 million new cases and 137,000 deaths in 2021.
Preclinical study showing chronic stress reduces endocannabinoid CB1 receptors in the ovBNST brain region, causing depression that is partially rescued by enhancing endocannabinoid signaling.
Daily-level analysis showing recreational cannabis users drink more on cannabis days (complementary), while medical users drink less (substitution) in Washington State.
Preclinical study showing exercise improves Parkinson's motor function through CB1 receptor modulation in the striatum, linking endocannabinoid signaling to exercise's therapeutic effects.
JAMA Network Open consensus statement establishing 6 core competencies and 26 sub-competencies for integrating medical cannabis education into medical school curricula.
Preclinical study showing a 100:1 CBD:THC ratio pretreatment rescues CGRP-induced migraine symptoms including light aversion and pain in mice.
Single-nucleus RNA study showing adolescent THC disrupts neuroblast migration in the nucleus accumbens, especially in mice with genetic psychiatric risk, providing a mechanism for gene-cannabis interaction.
Study of 521 Hispanic/Latinx cannabis users showing ethnic discrimination and minority stress independently predict greater cannabis use problems and barriers to reducing use.
Reviews the growing problem of accidental cannabis edible ingestion in young children, covering symptom recognition, emergency management, and prevention strategies for families.
A rigorous crossover trial found that even 20 mg of CBD altered the body's natural cannabinoid levels—with men and women showing different dose-response patterns.
Mayo Clinic review of CBD's potential in cardiovascular medicine, covering anti-inflammatory and cardioprotective mechanisms across pericarditis, ischemic heart disease, and heart failure.
Expert commentary urging caution about medical cannabis for adolescent Tourette syndrome, highlighting the gap between adult evidence and adolescent safety concerns.
Rat study finds adolescent THC vapor exposure doesn't increase alcohol consumption but alters the psychological framework of drinking behavior differently in males and females.
Among 353 older adults with chronic pain, the small minority using cannabis had more pain interference and depression over time—though the tiny sample size limits conclusions.
Review of cannabinoid therapies for rare and less-common disorders including unusual epilepsies, movement disorders, and skin diseases, with focus on advanced drug delivery strategies.
Rat study shows CBD and aerobic exercise synergistically protect insulin-producing beta cells in obesity through the PI3K/AKT/PDX1 pathway, with CBD driving functional improvement.
Rat study demonstrates CBD protects the heart from ischemia-reperfusion injury by boosting mitochondrial biogenesis and suppressing inflammation through the SIRT-1/PGC-1α pathway.
Statewide Michigan study using both self-report and urine testing finds 1 in 6 pregnancies involved cannabis use, strongly linked to depression, adverse childhood experiences, and socioeconomic factors.
Qualitative study reveals low-income pregnant cannabis users are primarily motivated by emotional regulation and mental health needs, highlighting systemic barriers to support and informed decision-making.
Review of how cannabis's 100+ compounds interact with molecular targets in the body, highlighting major gaps in understanding beyond THC and CBD, especially for acid cannabinoids.
Meta-analysis of 9 trials with 2,544 MS patients confirms cannabis-based therapies improve spasticity, especially with longer treatment duration, with mild side effects like dizziness and dry mouth.
Synthetic CBD analogues are over 13 times less toxic than natural CBD to brain cells while maintaining protective effects against alcohol-induced damage, supporting their development for alcohol use disorder.
Study finds cannabis use during pregnancy suppresses both pro- and anti-inflammatory immune signals in mothers, providing a potential biological mechanism for adverse birth outcomes.
Knockout mouse study challenges the theory that cannabis and opioid receptors interact directly, finding limited brain co-expression and no functional cross-dependence for pain relief or other effects.
Large ABCD Study finds prenatal cannabis exposure alters brain reward processing in children, with blunted striatal responses predicting psychotic-like experiences over 4 years of follow-up.
Three decades of national survey data show US teen cannabis use peaked in 1999 and declined since, but a historic shift has occurred — girls now use more than boys.
Predictive model using data from 12 countries estimates that cannabis decriminalization in Sweden would spike experimental use temporarily but could drive sustained increases in regular use.
Case report of cannabis hyperemesis syndrome developing during psychiatric admission for drug-induced psychosis, highlighting diagnostic challenges and the need for multidisciplinary cannabis-related care.
California birth data from 2007-2021 shows combining cannabis with alcohol during pregnancy adds 21% higher risk of small babies, while adding tobacco raises preterm birth risk by 44-68%.
Protocol for the first real-world on-track driving study testing whether medical cannabis patients are impaired at therapeutic doses, compared to alcohol at the legal driving limit.
Canadian impaired driving reports rose after 2018 cannabis legalization, but analysis suggests enhanced police enforcement and pandemic effects drove the increase more than cannabis sales themselves.
Among 616 Mexican American college students who'd never used cannabis, depressive symptoms predicted starting cannabis a year later—family factors didn't buffer it.
Five-year study of 1,379 first-psychosis patients finds cannabis-related psychosis follows a more chronic course than expected for substance-induced conditions, challenging treatment assumptions.
Lab study validates the Marijuana Purchase Task by showing hypothetical cannabis demand closely predicts actual purchasing and smoking behavior, with self-report explaining 66% of consumption variance.
The Cochrane Review found cannabis provides modest neuropathic pain relief for a minority of patients, but side effects are common—the benefit-harm balance is delicate.
Analysis of 20,000+ pregnancies across 19 states finds punitive prenatal substance use policies (child abuse charges, mandatory reporting) do not reduce drug use during pregnancy.